ArticleBreast cancer research and treatment2021
Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation.
Article in Breast cancer research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis.Human reproduction (Oxford, England) · 2022Pooled it
- Effect of letrozole on follicular fluid steroids concentrations in cancer patients undergoing oocyte cryopreservation.Journal of assisted reproduction and genetics · 2022Trial
- Desire for future children and interest in consultation with a fertility specialist among adolescent and young adult (AYA) cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Oncologic Safety of Preoperative Controlled Ovarian Stimulation for Fertility Preservation Among Women with Estrogen Receptor Positive Breast Cancer.Annals of surgical oncology · 2026Article
- Fertility and ovarian function preservation in young women with breast cancer: A joint analysis of the Joven & Fuerte and PREFER prospective studies.Breast (Edinburgh, Scotland) · 2026Article
- A journey mapping study of healthcare professionals' involvement in fertility preservation for cancer patients.Frontiers in oncology · 2026Article
- Outcomes of female fertility preservation with cryopreservation of oocytes or embryos in the Netherlands: a population-based study.Human reproduction (Oxford, England) · 2024Observational
- Changing the Perspective on Fertility Preservation for Women with Metastatic or Advanced Stage Cancer.Current oncology reports · 2024Review
- Is controlled ovarian stimulation safe in patients with hormone receptor-positive breast cancer receiving neoadjuvant chemotherapy?ESMO open · 2024Review
- Knowledge and intentions to use fertility preservation among urban Chinese cancer patients: A study from Hong Kong.PloS one · 2024Article
- Fertility and Pregnancy-Related Issues in YoungBreast cancer : basic and clinical research · 2024Review
- Disparities in Female Oncofertility Care in the United States: More Questions Than Answers.Life (Basel, Switzerland) · 2023Article
- Oocyte vitrification for fertility preservation following COS does not delay the initiation of neoadjuvant chemotherapy for breast cancer compared to IVM.Journal of assisted reproduction and genetics · 2023Article
- Article
- Article
- Fertility preservation in patients of childbearing age treated for breast cancer: A nationwide cohort study.Breast (Edinburgh, Scotland) · 2022Article
- Fertility Preservation During the COVID-19 Pandemic: Modified But Uncompromised.Women's health reports (New Rochelle, N.Y.) · 2022Article
- Female Oncofertility: Current Understandings, Therapeutic Approaches, Controversies, and Future Perspectives.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
purposeBreast cancer is the most common cancer in reproductive age women, and treatment can affect fertility; however, there is often concern regarding the safety of increased estradiol (E
methodsWe reviewed charts of women with breast cancer who contacted the FP patient navigator (PN) at Northwestern University from 01/2005-01/2018. Oncology and fertility outcome data were collected. Data were analyzed by Chi-square test or regression, as appropriate. Kaplan-Meier curves were used to examine breast cancer recurrence and survival. Statistical analyses were performed with SPSS IBM Statistics 26.0 for Windows.
results332 patients were included, of which 157 (47.3%) underwent FP. Median days to treatment after consulting the PN was 35 in the FP group and 21 in non-FP (p < 0.05). Cancer recurrence was noted in 7 (4.7%) FP patients and 13 (7.9%) non-FP patients (NS), and mortality in 5 (3.2%) FP patients and 7 (4.2%) non-FP patients (NS). Within the FP group, no significant differences were found in recurrence or mortality based on ER status, age, BMI, peak E
conclusionsFP is safe and effective in breast cancer patients, regardless of receptor status; E
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.